English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 2/5 criteria met. Data as of 01/11/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 51.60%
Price change 2019 → 2020: 38.87%
Price change 2020 → 2021: 58.53%
Price change 2021 → 2022: -38.36%
Price change 2022 → 2023: -12.05%
Price change 2023 → 2024: -16.40%
Price change 2024 → 2025: 26.55%
Price change 2025 → 2026: 41.06%
Price change 2026 (year to date): 41.97%
Financial growth
Revenue CAGR (8 years): 9.84%
Earnings CAGR (8 years): 11.34%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 1.53
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 29.30
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 0.00% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ERF.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Eurofins Scientific SE over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 6.1 bn | 603 m | 9.9 % | n/a |
| 2021 | 7.5 bn | 875 m | 11.7 % | +23.5 % |
| 2022 | 7.5 bn | 682 m | 9.1 % | -0.1 % |
| 2023 | 7.3 bn | 347 m | 4.8 % | -2.9 % |
| 2024 | 7.8 bn | 455 m | 5.8 % | +6.7 % |
| 2025 | 8.2 bn | 531 m | 6.5 % | +5.0 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Valuation and competitors
Eurofins Scientific SE compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Eurofins Scientific SE publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 7.4 bn | 704 m | 3.77 (3.50 / 3.87) | n/a | 1 |
| 2027 | 7.8 bn | 802 m | 4.29 (3.99 / 4.41) | n/a | 1 |
| 2028 | 8.3 bn | 895 m | 4.78 (4.45 / 4.91) | n/a | 1 |
Amounts in EUR, the reporting currency.
Track record against expectations: reported EPS above consensus 7 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 03/11/2026. An analyst rating or target is not a guarantee. Company data collected from its ERFSF listing (same ISIN).
Dividends and earnings
Eurofins Scientific SE: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 28/04/2026 | 0.720 | 30/04/2026 |
| 28/04/2025 | 0.600 | 30/04/2025 |
| 03/07/2024 | 0.500 | 05/07/2024 |
| 04/07/2023 | 1.00 | 06/07/2023 |
| 05/07/2022 | 1.00 | 07/07/2022 |
| 01/07/2021 | 0.680 | 05/07/2021 |
| 03/07/2019 | 0.288 | 05/07/2019 |
| 28/06/2018 | 0.240 | 02/07/2018 |
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 23/07/2026 | 2.10 | 1.91 | +9.9 % |
| 29/01/2026 | 1.26 | 1.25 | +0.8 % |
| 23/07/2025 | 1.64 | 1.71 | -4.1 % |
| 30/01/2025 | 1.36 | 1.51 | -9.9 % |
| 22/10/2024 | 1.64 | 1.71 | -4.1 % |
| 23/07/2024 | 0.83 | 1.49 | -44.3 % |
Stock splits
| Date | Operation |
|---|---|
| 19/11/2020 | split: 10 shares for 1 |
| 22/05/2000 | split: 10 shares for 1 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Eurofins Scientific SE
What is the revenue of Eurofins Scientific SE?
8.2 bn USD for fiscal year 2025, with net income of 531 m USD (net margin 6.5 %).
Does Eurofins Scientific SE pay a dividend?
Yes. Latest dividend: 0.720 per share, ex-dividend on 28/04/2026. Over 12 months: 0.720.
When does Eurofins Scientific SE report its next earnings?
The next release is expected on 02/03/2027. EPS expected by analysts: 1.80.
What do analysts say about Eurofins Scientific SE?
Out of 4 analysts: 2 buy or strong buy, 1 hold, 1 sell or strong sell.
What is the P/E ratio of Eurofins Scientific SE?
Trailing 12-month P/E of 27.8.
Is Eurofins Scientific SE stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR0014000MR3) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Eurofins Scientific SE have?
62,696 full-time employees according to the latest published profile.
Who runs Eurofins Scientific SE?
Gilles G. Martin is the company's chief executive.